ArticleCell2017
Cancer Evolution during Immunotherapy.
Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.BMC cancer · 2023Trial
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Tracing specificity of immune landscape remodeling associated with distinct anticancer treatments.iScience · 2025Article
- Integrative Analysis Reveals Differential Characteristics of DDR1 Mutant and Wild-type Gastric Cancers and Constructs their Prediction Models.Current medicinal chemistry · 2025Article
- Article
- Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.Acta pharmacologica Sinica · 2022Review
- Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives.Frontiers in oncology · 2022Review
- Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.Cancer medicine · 2021Review
- Biomarkers of immunotherapy in non-small cell lung cancer.Oncology letters · 2020Review
- An Overview of Cancer Prevention: Chemoprevention and Immunoprevention.Journal of cancer prevention · 2020Review
- Capturing transient antibody conformations with DNA origami epitopes.Nature communications · 2020Article
- Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.Theranostics · 2020Article
- Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma.Frontiers in immunology · 2019Article
- Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R.Acta pharmacologica Sinica · 2018Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.